Head and Neck Carcinoma Clinical Trials & Research at Providence Medical Group
Head and neck cancers start in the tissues and organs of the head and neck
and include cancers of the larynx (voice box), throat, lips, mouth, nose,
and salivary glands. Most head and neck cancers are squamous cell carcinomas
and begin in the moist tissues that line the mouth, nose and throat. Tobacco
use, heavy alcohol use, and infection with the human papillomavirus (HPV)
increase your risk of head and neck cancer.
Providence Medical Group is currently enrolling patients for the following
head and neck carcinoma clinical trials at this time:
Evolve study for participants with unresected locally advanced head and
neck squamous cell carcinoma, who have not progressed following definitive
concurrent chemoradiotherapy
Treatment agent: Volrustomig (MEDI5752) as Sequential Therapy Versus Observation
Physician: Dr. Yao Yao Pollock
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830
Study Resources:
Study Details | A Global Study of Volrustomig (MEDI5752) for Participants
With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
Following Definitive Concurrent Chemoradiotherapy | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort,
Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab
in Subjects with Locally Advanced or Metastatic Solid Tumors